The Importance of miRNA in the Diagnosis and Prognosis of Papillary Thyroid Cancer

Rogucki, Mariusz; Buczyńska, Angelika; Krętowski, Adam; Popławska-Kita, Anna

doi:10.3390/jcm10204738

Cited by 22 publications

(15 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To increase the diagnostic accuracy of using miRNAs, we assessed a combination of four miRNAs (miR-152-3p, miR-221-3p, miR-551b-3p, and miR-7-5p) with a calculated AUC of 0.841. Moreover, the AUC values obtained in our study are comparable to those previously published in the literature [ 16 , 36 , 47 ]. Other authors also proposed miR-221 measurement as a potential biomarker of PTC recurrence [ 18 ].…”

Section: Discussionsupporting

confidence: 90%

“…The results of our study are in line with the current knowledge about miRNAs in the pathogenesis of PTC. The theranostic utility of miRNAs and their prognostic potential in PTC have been demonstrated [ 16 ]. However, our analyses are of crucial importance for the exploration of the role of miRNA expression patterns in the pathogenesis of PTC.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, FNAB does not provide complete information about the clinical nature of tumors, such as the presence of angioinvasion features, which may affect further management [ 14 ]. As such, novel diagnostic biomarkers that are equivalent thyroid cancer diagnostic tools need to be identified [ 15 , 16 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Expression Profile and Diagnostic Significance of MicroRNAs in Papillary Thyroid Cancer

Rogucki

Sidorkiewicz

Niemira

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

The incidence of papillary thyroid cancer (PTC) has increased in recent years. To improve the diagnostic management of PTC, we propose the use of microRNAs (miRNAs) as a biomarker. Our aim in this study was to evaluate the miRNA expression pattern in PTC using NanoString technology. We identified ten miRNAs deregulated in PTC compared with reference tissue: miR-146b-5p, miR-221-3p, miR-221-5p, miR-34-5p, miR-551b-3p, miR-152-3p, miR-15a-5p, miR-31-5p, and miR-7-5p (FDR < 0.05; |fold change (FC)| ≥ 1.5). The gene ontology (GO) analysis of differentially expressed miRNA (DEM) target genes identified the predominant involvement of epidermal growth factor receptor (EGFR), tyrosine kinase inhibitor resistance, and pathways in cancer in PTC. The highest area under the receiver operating characteristic (ROC) curve (AUC) for DEMs was found for miR-146-5p (AUC = 0.770) expression, indicating possible clinical applicability in PTC diagnosis. The combination of four miRNAs (miR-152-3p, miR-221-3p, miR-551b-3p, and miR-7-5p) showed an AUC of 0.841. Validation by real-time quantitative polymerase chain reactions (qRT-PCRs) confirmed our findings. The introduction of an miRNA diagnostic panel based on the results of our study may help to improve therapeutic decision making for questionable cases. The use of miRNAs as biomarkers of PTC may become an aspect of personalized medicine.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Expression Profile and Diagnostic Significance of MicroRNAs in Papillary Thyroid Cancer

Rogucki

Sidorkiewicz

Niemira

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…Therefore, a detailed evaluation of disturbed transcriptomic pathways related to T13 and T18 and the subsequent metabolic pathway disturbances may result in novel findings regarding trisomy-related abnormalities. Undoubtedly, studies may highlight deregulated pathways, and their detailed identification might become the basis for further research in T13 and T18 [ 47 , 94 ].…”

Section: Genetic Basis Of the T13 And T18 Pathogenesesmentioning

confidence: 99%

Future Perspectives in Oxidative Stress in Trisomy 13 and 18 Evaluation

Buczyńska

Sidorkiewicz

Hameed

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

Autosomal aneuploidies are the most frequently occurring congenital abnormalities and are related to many metabolic disorders, hormonal dysfunctions, neurotransmitter abnormalities, and intellectual disabilities. Trisomies are generated by an error of chromosomal segregation during cell division. Accumulating evidence has shown that deregulated gene expression resulting from the triplication of chromosomes 13 and 18 is associated with many disturbed cellular processes. Moreover, a disturbed oxidative stress status may be implicated in the occurrence of fetal malformations. Therefore, a literature review was undertaken to provide novel insights into the evaluation of trisomy 13 (T13) and 18 (T18) pathogeneses, with a particular concern on the oxidative stress. Corresponding to the limited literature data focused on factors leading to T13 and T18 phenotype occurrence, the importance of oxidative stress evaluation in T13 and T18 could enable the determination of subsequent disturbed metabolic pathways, highlighting the related role of mitochondrial dysfunction or epigenetics. This review illustrates up-to-date T13 and T18 research and discusses the strengths, limitations, and possible directions for future studies. The progressive unification of trisomy-related research protocols might provide potential medical targets in the future along with the implementation of the foundation of modern prenatal medicine.

show abstract

“…In addition to this, the evaluation using FNAB on a series of miRNAs differentially expressed between benign and malignant thyroid lesions has now been verified by several studies. In particular, the evaluation of the different combinations of expression of some miRNAs (miR-221, miR-222, miR-146b, and miR-181b) led to the conclusion that miRNAs have a very promising role in defining the correct diagnosis of the disease [142].…”

Section: The Impact Of the Identification Of Ncrnas In The Clinical M...mentioning

confidence: 99%

Noncoding RNAs in Thyroid-Follicular-Cell-Derived Carcinomas

Martino

Esposito

Capone

et al. 2022

Cancers

View full text Add to dashboard Cite

Among the thyroid neoplasias originating from follicular cells, we can include well-differentiated carcinomas, papillary (PTC) and follicular (FTC) thyroid carcinomas, and the undifferentiated anaplastic (ATC) carcinomas. Several mutations in oncogenes and tumor suppressor genes have already been observed in these malignancies; however, we are still far from the comprehension of their full regulation-altered landscape. Even if only 2% of the human genome has the ability to code for proteins, most of the noncoding genome is transcribed, constituting the heterogeneous class of noncoding RNAs (ncRNAs), whose alterations are associated with the development of several human diseases, including cancer. Hence, many scientific efforts are currently focused on the elucidation of their biological role. In this review, we analyze the scientific literature regarding the involvement of microRNAs (miRNAs), long noncoding RNAs (lncRNAs), and pseudogenes in FTC, PTC, and ATC. Recent findings emphasized the role of lncRNAs in all steps of cancer progression. In particular, lncRNAs may control progression steps by regulating the expression of genes and miRNAs involved in cell proliferation, apoptosis, epithelial–mesenchymal transition, and metastatization. In conclusion, the determination of the diagnosis, prognosis, and treatment of cancer based on the evaluation of the ncRNA network could allow the implementation of a more personalized approach to fighting thyroid tumors.

show abstract

The Importance of miRNA in the Diagnosis and Prognosis of Papillary Thyroid Cancer

Cited by 22 publications

References 76 publications

Expression Profile and Diagnostic Significance of MicroRNAs in Papillary Thyroid Cancer

Expression Profile and Diagnostic Significance of MicroRNAs in Papillary Thyroid Cancer

Future Perspectives in Oxidative Stress in Trisomy 13 and 18 Evaluation

Noncoding RNAs in Thyroid-Follicular-Cell-Derived Carcinomas

Contact Info

Product

Resources

About